Chemotherapy for Refractory Epithelial Ovarian Cancer
Author:
Publisher
Elsevier
Reference164 articles.
1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996
2. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclo-phosphamide in women with advanced epithelial ovarian cancer: Three-year results;Piccart;J Natl Cancer Inst,2000
3. Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III ovarian cancer: A Gynecologic Oncology Group study (GOG 158) [abstract 1373];Ozols;Proc Am Soc Clin Oncol,1999
4. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials;Blackledge;Br J Cancer,1989
5. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J Clin Oncol,1991
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emerging treatments for ovarian cancer;Expert Opinion on Emerging Drugs;2003-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3